AUTL 株価推移チャート
AUTL 財務
Autolus Therapeutics PLC
$1.57
-2.48%
$-0.04
終値： May 08, 16:00:00 GMT-4
$1.63
3.82%
$0.05
アフターマーケット：May 08, 20:00:00 GMT-4
戻る
Autolus Therapeutics PLC (AUTL) 財務
主要データ
前終値
$1.61
始値
$1.62
当日レンジ
$1.55 - $1.63
52週レンジ
$1.15 - $2.7
取引高
1.1M
平均取引高
1.8M
配当利回り
--
1株当たり利益(TTM)
-1.80
時価総額
$433.8M
AUTLとは何ですか？
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
